Patents by Inventor Joseph J. Buggy

Joseph J. Buggy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF
    Publication number: 20190184196
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: October 18, 2018
    Publication date: June 20, 2019
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER
    Publication number: 20190167687
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Application
    Filed: July 6, 2018
    Publication date: June 6, 2019
    Inventors: Jun Chen, Joseph J. Buggy, Laurence Elias
  • METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20180311153
    Abstract: Disclosed herein are methods for treating an individual diagnosed with ABC-DLBCL. The methods include administering to the individual an inhibitor of Bruton's tyrosine kinase (Btk).
    Type: Application
    Filed: December 1, 2017
    Publication date: November 1, 2018
    Inventors: Joseph J. Buggy, Louis M. Staudt, Wyndham H. Wilson
  • Formulations of histone deacetylase inhibitor and uses thereof
    Patent number: 10105552
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 23, 2018
    Assignee: Pharmacyclics LLC
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20180280395
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: May 2, 2018
    Publication date: October 4, 2018
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20180256581
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 13, 2018
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS
    Publication number: 20180193345
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Application
    Filed: October 23, 2017
    Publication date: July 12, 2018
    Inventors: Joseph J. Buggy, Laurence Elias
  • Use of inhibitors of Bruton's tyrosine kinase (Btk)
    Patent number: 10016435
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: July 10, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Methods for the treatment of HER2 amplified cancer
    Patent number: 10016434
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 10, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Jun Chen, Joseph J. Buggy, Laurence Elias
  • Use of inhibitors of Bruton'S tyrosine kinase (Btk)
    Patent number: 10004745
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: June 26, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Use of inhibitors of Bruton's tyrosine kinase (Btk)
    Patent number: 10004746
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: June 26, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER
    Publication number: 20180071294
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Application
    Filed: July 18, 2017
    Publication date: March 15, 2018
    Inventors: Jun Chen, Joseph J. Buggy, Laurence Elias
  • TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY
    Publication number: 20180071293
    Abstract: Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.
    Type: Application
    Filed: July 14, 2017
    Publication date: March 15, 2018
    Inventors: Joseph J. Buggy, Tarak D. Mody, Richard B. Love, John C. Byrd, Betty Y. Chang, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20180036313
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: September 26, 2017
    Publication date: February 8, 2018
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20180015091
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: July 26, 2017
    Publication date: January 18, 2018
    Inventors: JOSEPH J. BUGGY, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20170362246
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Application
    Filed: August 31, 2017
    Publication date: December 21, 2017
    Inventors: Joseph J. Buggy, Wei Chen, Lee Honigberg, David J. Loury, Zhengying Pan, Erik J. Verner
  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF
    Publication number: 20170333731
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: December 21, 2016
    Publication date: November 23, 2017
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • Use of inhibitors of bruton'S tyrosine kinase (BTK)
    Patent number: 9814721
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: November 14, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Use of inhibitors of bruton's tyrosine kinase (BTK)
    Patent number: 9801881
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: October 31, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Use of inhibitors of bruton's tyrosine kinase (Btk)
    Patent number: 9801883
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 31, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody